Lisata Therapeutics (NASDAQ:LSTA) Stock Price Up 2.5%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) shares rose 2.5% during mid-day trading on Thursday . The company traded as high as $2.86 and last traded at $2.85. Approximately 1,130 shares traded hands during trading, a decline of 92% from the average daily volume of 13,442 shares. The stock had previously closed at $2.78.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Lisata Therapeutics in a report on Friday, March 1st.

Lisata Therapeutics Price Performance

The stock has a market cap of $23.67 million, a P/E ratio of -1.10 and a beta of 1.04. The stock’s fifty day simple moving average is $3.03 and its 200-day simple moving average is $2.69.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.20. Analysts forecast that Lisata Therapeutics, Inc. will post -3.08 EPS for the current year.

Hedge Funds Weigh In On Lisata Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of LSTA. Dimensional Fund Advisors LP acquired a new stake in shares of Lisata Therapeutics in the third quarter worth $57,000. State Street Corp purchased a new stake in Lisata Therapeutics in the 3rd quarter worth about $66,000. Citadel Advisors LLC acquired a new stake in Lisata Therapeutics during the 2nd quarter worth about $64,000. BlackRock Inc. purchased a new position in Lisata Therapeutics during the 3rd quarter valued at about $263,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Lisata Therapeutics in the 3rd quarter valued at about $467,000. Institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.